Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04243551 · ClinicalTrials.gov registry record · Phase 2
Prospective, Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Symptomatic CD Patients
A Phase 2 study, sponsored by Entero Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 83
- Enrollment target
NCT04243551 is a Phase 2 study that was terminated before completion, run by Entero Therapeutics. The registered enrollment target is 83 participants.
The verdict
NCT04243551, a Phase 2 study, was terminated before completion, sponsored by Entero Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 83 participants
- Enrollment target
Study Summary
This is a phase 2b, multicenter, prospective, randomized, double-blind, placebo-controlled, crossover study in symptomatic celiac disease patients attempting a GFD for at least one year prior to screening.
Interventions
- OTHER Placebo
- DRUG Latiglutenase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2019-11-01 |
| Est. Completion | 2023-10-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04243551
The ClinicalTrials.gov registry entry for NCT04243551 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Entero Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04243551 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04243551 about?
NCT04243551 is a clinical study titled "Prospective, Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Symptomatic CD Patients". This is a phase 2b, multicenter, prospective, randomized, double-blind, placebo-controlled, crossover study in symptomatic celiac disease patients attempting a GFD for at least one year prior to screening.
What is the current status of trial NCT04243551?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 83 participants. The study started on 2019-11-01. Estimated completion is 2023-10-31.
What interventions are being tested in trial NCT04243551?
The interventions under investigation include: Placebo (OTHER), Latiglutenase (DRUG).
Who is sponsoring clinical trial NCT04243551?
This trial is sponsored by Entero Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.